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The term “clonal B cell lymphocytosis of marginal zone origin” (CBL-MZ)1,2 has recently been suggested
for asymptomatic individuals whose routine blood count shows a persistent modest lymphocytosis that
is usually accompanied by bone marrow involvement. This immunophenotype is suggestive of marginal
zone/postgerminal center derivation, but no other features of a chronic B cell lymphoproliferative
disorder are found, other than a low-level paraprotein in some cases. Cases with a clonal lymphocyte
count ,5 3 109/L would fall within the revised World Health Organization (WHO) category of
non–chronic lymphocytic leukemia-type monoclonal B-cell lymphocytosis. In 3 previous series of CBL-
MZ consisting of 102, 53, and 16 cases with median follow-ups (FUs) of 60, 34, and 44 months,
respectively,1,3,4 the overall incidence of progression was 15.7%, with the majority (11.1%) developing
splenomegaly that frequently did not require treatment. However, it remains unclear whether CBL-MZ is
the precursor to 1 or several well-defined WHO entities and what factors predict disease progression.
To address this, we performed a genomic analysis of a well-characterized cohort of CBL-MZ cases with
long FU and provide evidence to show that CBL-MZ is not a single biological entity.
This study includes data from 37 patients with CBL-MZ diagnosed and managed at the Royal
Bournemouth Hospital. Clinical, routine laboratory, morphological, immunophenotypic, immunogenetic,
and cytogenetic data have been reported on 36 cases using previously described methods.1 Informed
patient consent was obtained according to the Declaration of Helsinki, and the ethical aspect of the
study was approved by the Somerset Research and Ethics Committee.
DNA from blood-derived tumor cells (n5 37) at diagnosis was analyzed with a bespoke HaloPlex Target
Enrichment System (Agilent Technologies) that enriched 2.39 Mb of genomic DNA for the coding
regions of 768 genes, as previously described.5 From this panel, the following candidate genes were
selected for Sanger validation (primers and conditions are listed in supplemental Table 1) based on the
high prevalence of somatic mutations in similar mature B-cell malignancies: KLF2 andNOTCH2 (splenic
marginal zone lymphoma [SMZL]),5-9 CCND3 and BCOR (splenic diffuse red pulp lymphoma
[SDRPL]),10,11 MAP2K1 (hairy cell variant [HCL-v]),12 MYD88 (lymphoplasmacytic lymphoma [LPL]),13
BRAF V600E (hairy cell leukemia and nodal marginal zone lymphoma [MZL]),14,15 and TNFAIP3 and
TP53 (not disease specific). DNA from buccal cells (n 5 22) was used to confirm the somatic origin of
14 of 15 variants identified in 7 of these genes.
The study included 20 men and 17 women (1.2:1 ratio). The median age at presentation was 73.2 years
(range 47.8-95.5 years). Key clinical and laboratory data and additional demographic and cytogenetic
data are provided in Table 1 and supplemental Table 2, respectively. Lymphocyte morphology was
heterogeneous in all cases, with a variable percentage of villous and lymphoplasmacytoid cells. No case
had the typical morphological features of HCL-v or SDRPL. The immunophenotype was uniform, with
expression of moderate SmIg, CD19, and CD49d and lack of CD10, CD38, and CD5, with the
exception of 5 cases with weak CD5 positivity.
With a median FU of 9.6 years (range 2.5-22.4), 28 of 37 cases (75.7%) remained stable of whom
11 have died after a median FU of 8.8 years (range 2.5-14.3), and 17 remained stable after a median
FU of 9.7 years (range 2.9-14.6 years). Nine of 37 (24.3%) cases showed evidence of progressive
disease, and 3 died. The median time to progression was 69 months (range 47-175). Seven patients
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(cases 1-5, 7, and 9) developed splenomegaly that was accompa-
nied by progressive lymphocytosis in 4 cases. In 2 patients,
splenic histopathology confirmed a diagnosis of SMZL. In 3
patients, lymphocyte morphology and marrow histology at progres-
sion, combined with immunogenetic and karyotypic features, were
also consistent with SMZL. Two cases, classified as splenic B cell
lymphoma/leukemia unclassifiable, were too frail for further in-
vestigation; 1 (case 9) had a t(2;7)(p11;q21.2) translocation
at diagnosis, which has been associated with MZLs,16,17 and 1
(case 1) exhibited progressive lymphocytosis with large circulating
lymphoid cells. Case 8 developed heavy marrow infiltration with
small nonvillous lymphocytes in conjunction with a low-level IgGK
paraprotein and cytogenetic analysis showing del(6q) and iso(18q);
LPL was considered a likely diagnosis. Case 6 underwent biopsy
of orbital and abdominal wall masses, both of which showed
histological and immunophenotypic features of MZL.
Fifteen genomic mutations, involving all candidate genes screened,
with the exception of BCOR and BRAF V600E, were identified in 12
cases (Table 1). The most frequent was MYD88 in 5 (13.5%) cases,
involving L265P (n 5 3) or S219C (n 5 2) and indicating that
screening CBL-MZ cases only for the L265P mutation is likely to miss
cases with alternate MYD88 mutations. Three patients had histolog-
ically proven SMZL, 1 had a t(2;7)(p11;q21.2) translocation, and 1
had LPL. None of these cases had a mutation of CXCR4 (data not
shown). Three cases (8.1%) had mutations of TP53, all accompanied
by TP53 loss, and 3 had PEST domain CCND3 mutations, although
none had the typical features of SDRPL, and all had stable disease.
The sole case with a MAP2K1 mutation (E203K; deleterious and
damaging by Mutationtaster and Polyphen2, respectively) was stable
with a FU of 66 months. Extended immunophenotypic analysis
showed expression of SmIgG, FMC7, CD22, and CD11c (weak)
and lack of CD103 and CD25, consistent with HCL-v, splenic B cell
lymphoma/leukemia unclassifiable, or SMZL. NOTCH2 and KLF2
mutations were present in a single case that used IGHV1-2*04 and
progressed to SMZL. The patient with orbital lymphoma had the
recently noted association of a TNFAIP3 mutation and IGHV4-34
usage in this subset of MZL.18 Three patients had repeat genomic
analysis at evolution, and no new mutations were found.
Neither cytogenetic nor immunogenetic data measured at pre-
sentation correlated with the natural history of CBL-MZ. In contrast,
5 of 9 patients with progressive disease had $1 mutation
(3 MYD88 mutations; single cases with TP53, NOTCH2, KLF2,
TNFAIP3 mutations), of which TP53 and NOTCH2 mutations have
been associated with disease progression in MZLs, compared with
6 of 28 patients with stable disease (P 5 .034). Five of 6 patients
with stable disease who had mutations (3 CCND3 mutations, 2
mutations in both MYD88 and TP53) died of unrelated causes.
Their median FU was considerably shorter (39 months) than that of
the other stable cases, raising the question of whether their CBL-
MZ would have progressed with extended FU.
In summary, our clinical outcome data indicate that CBL-MZ usually
pursues a stable course, but the higher rate of progression in this
study compared with previous studies probably reflects the longer FU
and reinforces the need for long-term clinical management and
patient education on when to seek medical advice. CBL-MZ can
evolve into several well-defined WHO disorders, especially those of
marginal zone origin. The genomic data are consistent with this
observation because, although the genomic abnormalities in CBL-MZT
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overlap with those found in any of the well-defined entities into
which it could evolve, the incidence of mutations is lower and does
not mirror any specific disease. However, important caveats are the
relatively small number of cases in the current study and the lack
of concordance among genomic studies in other rare disorders,
such as HCL-v19and SDRPL.11,20,21 Further larger studies, ideally
including immunogenetic, whole genomic sequencing, and epige-
netic data, will be required to confirm the relationship between
CBL-MZ and established WHO disorders and to identify additional
drivers of progressive disease. In the interim, CBL-MZ remains a
useful term to define a group of asymptomatic patients with well-
defined clinical, morphological, and immunophenotypic features
requiring long-term FU.
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